Cell Source, Inc. (CLCS)
USD 0.28
(-16.67%)
USD 0.28
(-16.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.32 Million USD | -2.97% |
| 2022 | -5.16 Million USD | 24.37% |
| 2021 | -6.83 Million USD | -24.29% |
| 2020 | -5.49 Million USD | -14.93% |
| 2019 | -4.78 Million USD | -125.91% |
| 2018 | -2.11 Million USD | 31.31% |
| 2017 | -3.08 Million USD | -218.51% |
| 2016 | -967.78 Thousand USD | 61.35% |
| 2015 | -2.5 Million USD | 38.28% |
| 2014 | -4.05 Million USD | -15732.83% |
| 2013 | -25.62 Thousand USD | -1442.02% |
| 2012 | -1661.91 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.27 Million USD | -21.48% |
| 2024 Q2 | -1.48 Million USD | -16.73% |
| 2023 Q3 | -1.33 Million USD | -7.77% |
| 2023 FY | -5.32 Million USD | -2.97% |
| 2023 Q4 | -1.04 Million USD | 21.54% |
| 2023 Q1 | -1.69 Million USD | -26.49% |
| 2023 Q2 | -1.24 Million USD | 26.6% |
| 2022 Q2 | -1.22 Million USD | 5.05% |
| 2022 FY | -5.16 Million USD | 24.37% |
| 2022 Q3 | -1.25 Million USD | -2.04% |
| 2022 Q1 | -1.29 Million USD | -54.8% |
| 2022 Q4 | -1.33 Million USD | -6.78% |
| 2021 Q4 | -835.01 Thousand USD | 53.6% |
| 2021 FY | -6.83 Million USD | -24.29% |
| 2021 Q2 | -1.31 Million USD | 13.88% |
| 2021 Q3 | -1.79 Million USD | -37.05% |
| 2021 Q1 | -1.52 Million USD | -19.67% |
| 2020 Q4 | -1.27 Million USD | 2.56% |
| 2020 Q1 | -813.74 Thousand USD | -41.27% |
| 2020 Q2 | -1.16 Million USD | -43.13% |
| 2020 FY | -5.49 Million USD | -14.93% |
| 2020 Q3 | -1.3 Million USD | -12.27% |
| 2019 FY | -4.78 Million USD | -125.91% |
| 2019 Q1 | -1.45 Million USD | -160.58% |
| 2019 Q2 | -952.98 Thousand USD | 34.66% |
| 2019 Q3 | -1.48 Million USD | -56.14% |
| 2019 Q4 | -576.03 Thousand USD | 61.29% |
| 2018 Q2 | -360.72 Thousand USD | 49.35% |
| 2018 FY | -2.11 Million USD | 31.31% |
| 2018 Q4 | -559.7 Thousand USD | -38.26% |
| 2018 Q3 | -404.82 Thousand USD | -12.22% |
| 2018 Q1 | -712.18 Thousand USD | -16.91% |
| 2017 Q1 | -1.14 Million USD | -184.22% |
| 2017 Q3 | -508.54 Thousand USD | 38.14% |
| 2017 Q2 | -822.09 Thousand USD | 28.06% |
| 2017 FY | -3.08 Million USD | -218.51% |
| 2017 Q4 | -609.14 Thousand USD | -19.78% |
| 2016 Q1 | -820.44 Thousand USD | -16.69% |
| 2016 Q2 | -700.78 Thousand USD | 14.58% |
| 2016 FY | -967.78 Thousand USD | 61.35% |
| 2016 Q3 | -803.35 Thousand USD | -14.64% |
| 2016 Q4 | 1.35 Million USD | 268.89% |
| 2015 FY | -2.5 Million USD | 38.28% |
| 2015 Q4 | -703.11 Thousand USD | -4.41% |
| 2015 Q3 | -673.43 Thousand USD | -17.96% |
| 2015 Q1 | -556.64 Thousand USD | 64.42% |
| 2015 Q2 | -570.91 Thousand USD | -2.56% |
| 2014 Q1 | -11.89 Thousand USD | 29.07% |
| 2014 Q3 | -686.49 Thousand USD | 30.38% |
| 2014 Q2 | -986.07 Thousand USD | -8187.76% |
| 2014 FY | -4.05 Million USD | -15732.83% |
| 2014 Q4 | -1.56 Million USD | -127.92% |
| 2013 Q4 | -16.77 Thousand USD | -614.4% |
| 2013 Q3 | -2348.00 USD | 99.71% |
| 2013 Q2 | -803.99 Thousand USD | -16601.08% |
| 2013 FY | -25.62 Thousand USD | -1442.02% |
| 2013 Q1 | -4814.00 USD | 0.0% |
| 2012 FY | -1661.91 USD | 0.0% |
| 2012 Q3 | -24.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -298.464% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 23.796% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 110.044% |
| Nascent Biotech, Inc. | -2.08 Million USD | -154.886% |
| Rebus Holdings, Inc. | -1.02 Million USD | -421.687% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 108.17% |
| Qrons Inc. | -789.34 Thousand USD | -574.128% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -741.422% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 91.5% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1180.742% |
| Skye Bioscience, Inc. | -37.64 Million USD | 85.865% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 92.902% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 19.083% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1846.296% |
| SQZ Biotechnologies Company | -79.46 Million USD | 93.304% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -83.973% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -192.289% |
| Mesoblast Limited | -87.95 Million USD | 93.95% |
| Marizyme, Inc. | -65.34 Million USD | 91.857% |
| Genus plc | 7.9 Million USD | 167.357% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 51.145% |
| Pharming Group N.V. | -10.54 Million USD | 49.552% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -145.238% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -43.42% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 39.833% |
| ContraFect Corporation | -65.15 Million USD | 91.833% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -8.906% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -208.038% |
| IMV Inc. | -36.48 Million USD | 85.416% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 33.977% |
| MultiCell Technologies, Inc. | -380.07 USD | -1399961.041% |
| ONE Bio Corp. | 8.67 Million USD | 161.328% |
| Accustem Sciences Inc. | -3.74 Million USD | -42.035% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 89.706% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -319.941% |
| Q BioMed Inc. | -2.05 Million USD | -159.307% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -42.545% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -123.499% |
| Biomind Labs Inc. | -1.21 Million USD | -338.205% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 91.091% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -71.554% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 32.669% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -172.988% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -35431.597% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 66.473% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 8.527% |
| GB Sciences, Inc. | -1.36 Million USD | -290.784% |
| Alpha Cognition Inc. | -13.77 Million USD | 61.364% |
| HST Global, Inc. | -146.21 Thousand USD | -3539.431% |
| CSL Limited | 2.64 Billion USD | 100.201% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -203.243% |
| Halberd Corporation | -79.67 Thousand USD | -6578.563% |
| Enzolytics Inc. | -2.17 Million USD | -144.448% |
| Agentix Corp. | -1.37 Million USD | -287.219% |
| Resverlogix Corp. | -3.61 Million USD | -47.402% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -67.786% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.197% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 5529.808% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 176.845% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -33.935% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -75.842% |
| AVAX Technologies, Inc. | -6.41 Million USD | 17.033% |
| Zenith Capital Corp. | -10.59 Million USD | 49.781% |
| Genscript Biotech Corporation | -95.47 Million USD | 94.427% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -22794.811% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -28.348% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -8704.034% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -165.382% |
| Kadimastem Ltd | -3.3 Million USD | -60.888% |
| Helix BioMedix, Inc. | -1.05 Million USD | -403.875% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -39.335% |
| BioStem Technologies, Inc. | -8.48 Million USD | 37.272% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1105.615% |
| LadRx Corporation | 400.44 Thousand USD | 1428.831% |
| Regen BioPharma, Inc. | 1.02 Million USD | 619.899% |
| Regen BioPharma, Inc. | 1.02 Million USD | 619.899% |
| NovAccess Global Inc. | -4.76 Million USD | -11.575% |
| Affymax, Inc. | -14.42 Million USD | 63.109% |
| Itoco Inc. | -1.86 Million USD | -184.71% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -19.779% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -218.826% |
| Mobile Lads Corp. | -2.26 Million USD | -135.109% |
| CytoDyn Inc. | -49.84 Million USD | 89.324% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -6632.899% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2232.566% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -465.167% |
| SYBLEU INC | -180.3 Thousand USD | -2851.245% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -229.949% |
| International Stem Cell Corporation | -131 Thousand USD | -3961.994% |
| Bioxytran, Inc. | -4.28 Million USD | -24.327% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -9704.71% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -110.304% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 88.931% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -151.713% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -581.432% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -67.968% |
| Neutra Corp. | -233.46 Thousand USD | -2179.233% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 73.776% |
| PureTech Health plc | -65.69 Million USD | 91.9% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 74.978% |
| IXICO plc | -1.17 Million USD | -351.716% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 46.397% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 90.685% |
| CSL Limited | 2.64 Billion USD | 100.201% |
| Cellectis S.A. | -103.17 Million USD | 94.842% |